In an interview with Targeted Oncology, Dr. David S. Hong discusses bispecific t-cell engagers and their benefits, ongoing challenges related to the therapeutics, the hematologic malignancies that respond best to multitargeted platforms, implications moving forward, and more.

“Everyone is excited about the fact that these are new therapies and that they have the opportunity to help overcome mechanisms of resistance, mechanisms of tumor heterogeneity, and perhaps just overall be more efficacious than even single-agent or combination immunotherapy regimens that have been in clinical trials for the last several years.” – David S. Hong, MD

To read the full interview, visit Targeted Oncology.

Tags: bispecific t cell engagers, patient care, bite